Long-term maintenance of prognostic value of survivin and its relationship with p53 in T4 breast cancer patients

Ionta,Maria T.; Perra,Maria T.; Atzori,Francesco; Maxia,Cristina; Pusceddu,Valeria; Demurtas,Paolo; Deidda,Maria C.; Piras,Franca; Frau,Barbara; Murtas,Daniela; Minerba,Luigi; Massidda,Bruno; Sirigu,Paola

doi:10.3892/etm_00000010

Long-term maintenance of prognostic value of survivin and its relationship with p53 in T4 breast cancer patients

Authors:
- Maria T. Ionta
- Maria T. Perra
- Francesco Atzori
- Cristina Maxia
- Valeria Pusceddu
- Paolo Demurtas
- Maria C. Deidda
- Franca Piras
- Barbara Frau
- Daniela Murtas
- Luigi Minerba
- Bruno Massidda
- Paola Sirigu
View Affiliations

Affiliations: Department of Medical Oncology, University of Cagliari, I-09042 Monserrato (CA), Italy
Published online on: January 1, 2010 https://doi.org/10.3892/etm_00000010
Pages: 59-64

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A large proportion of human tumors show deregulated expression of a variety of proteins that play a crucial role in the execution of the apoptotic program. Survivin belongs to the family of inhibitor of apoptosis proteins which were originally identified in baculoviruses. Ectopic expression of survivin conveys resistance to apoptosis to a variety of stimuli, and survivin is one of the most abundantly overexpressed genes in human tumors such as breast cancer. In this study we examined the expression of survivin protein in a series of T4 breast cancers to identify any correlation with long-term patient outcomes. Moreover, we investigated the hypothesis of a possible association between p53 and survivin as a factor further complicating the outcome. Archival specimens from 53 T4 breast cancer patients were included in the study and treated for the immunohistochemical localization of survivin and p53 using the streptavidin-biotin alkaline phosphatase method. The immunoreactivity was evaluated semiquantitatively according to the percentage of cells stained. Forty percent of tumors were positive for survivin. Statistical analysis revealed that survivin expression negatively influenced the 5- and 10-year disease-free and overall patient survival. In multivariate analysis, survivin expression was a significant independent prognostic indicator of worse outcome in overall survival [hazard ratio (HR)=2.61]. Our results showed that survivin is associated with a worse prognosis in patients with T4 breast cancer, and remarkably its prognostic relevance is maintained even long-term. Notably, p53 (HR=3.2) seems to negatively enhance the effect of survivin on survival.

View Figures

View References

1.	Ferlay J, Bray F, Pisani P and Parkin DM; GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Press. Lyon: 2004.
2.	Dowsett M and Dunbier AK: Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res. 14:8019–8026. 2008. View Article : Google Scholar : PubMed/NCBI
3.	Altieri DC: Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem. 269:3139–3142. 1994.PubMed/NCBI
4.	Altieri DC: Splicing of effector cell protease receptor-1 mRNA is modulated by an unusual retained intron. Biochemistry. 33:13848–13855. 1994. View Article : Google Scholar : PubMed/NCBI
5.	Mita AC, Mita MM, Nawrocki ST and Giles FJ: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 14:5000–5005. 2008. View Article : Google Scholar : PubMed/NCBI
6.	Ambrosini G, Adida C and Altieri DC: A novel antiapoptosis gene, survivin expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
7.	Adida C, Crotty PL, McGrath J, et al: Developmentary regulated expression of the novel cancer antiapoptosis gene survivin in human and mouse differentiation. Am J Pathol. 152:43–49. 1998.PubMed/NCBI
8.	Olie RA, Simões-Wüst AP, Baumann B, et al: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60:2805–2809. 2000.
9.	Sah NK, Khan Z, Khan GJ and Bisen PS: Structural, functional and therapeutic biology of survivin. Cancer Lett. 244:164–171. 2006. View Article : Google Scholar : PubMed/NCBI
10.	O'Driscoll L, Linehan R, Kennedy MS, et al: Lack of prognostic significance of survivin, survivin-ΔEx3, survivin-2B, galectin-3, bag-1, bax-α and MRP-1 mRNAs in breast cancer. Cancer Lett. 201:225–236. 2003.
11.	Hinnis AR, Luckett JCA and Walker RA: Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer. 96:639–645. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Tanaka K, Iwamoto S, Gon G, et al: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 6:127–134. 2000.PubMed/NCBI
13.	Bertheau P, Espié M, Turpin E, et al: TP53 status and response to chemotherapy in breast cancer. Pathobiology. 75:132–139. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Brennan DJ, Rexhepaj E, O'Brien SL, et al: Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res. 14:2681–2689. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Hayward JL, Carbone PP, Heusen JC, et al: Assessment of response to therapy in advanced breast cancer. Br J Cancer. 35:292–298. 1977. View Article : Google Scholar : PubMed/NCBI
16.	Sataloff DM, Mason BA, Prestipino AJ, et al: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 180:297–306. 1995.PubMed/NCBI
17.	Li F and Ling X: Survivin study: an update of ‘what is the next wave’? J Cell Physiol. 208:476–486. 2006.
18.	Dohi T, Beltrami E, Wall NR, Plescia J and Altieri DC: Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 114:1117–1127. 2004. View Article : Google Scholar : PubMed/NCBI
19.	Li XN, Shu Q, Su JM, et al: Differential expression of survivin splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol. 33:67–76. 2007.PubMed/NCBI
20.	Altieri DC and Marchisio PC: Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest. 79:1327–1333. 1999.PubMed/NCBI
21.	Kennedy SM, O'Driscoll L, Purcell R, et al: Prognostic importance of survivin in breast cancer. Br J Cancer. 88:1077–1083. 2003. View Article : Google Scholar : PubMed/NCBI
22.	Ponnelle T, Chapusot C, Martin L, et al: Cellular localisation of survivin: impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol. 131:504–510. 2005. View Article : Google Scholar : PubMed/NCBI
23.	Xie D, Zeng YX, Wang HJ, et al: Expression of cytoplasmic and nuclear survivin in primary and secondary human glioblastoma. Br J Cancer. 94:108–114. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Piras F, Murtas D, Minerba L, et al: Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology. 50:835–842. 2007. View Article : Google Scholar : PubMed/NCBI
25.	Mirza A, McGuirk M, Hockenberry TN, et al: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 21:2613–2622. 2002. View Article : Google Scholar : PubMed/NCBI